Developer docs
API playgroundTry for free, no card

Search company profiles

Coriolis Pharma

Full company profile

uuid00076xj

Namestring
Coriolis Pharma
Legal namestring
Coriolis Pharma Research GmbH
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Coriolis Pharma is a privately-held contract research and development organization (CRDO) founded in 2008 in Martinsried, Germany, by Prof. Dr. Gerhard Winter of LMU Munich. The company specializes in formulation research, analytical services, and drug product manufacturing for biopharmaceutical drugs across multiple therapeutic modalities, including monoclonal antibodies, peptides, therapeutic proteins, gene and cell therapies, viral vectors, nucleic acid therapeutics, and vaccines. It serves pharmaceutical and biotech clients ranging from early-stage developers to large multinational pharmaceutical corporations, supporting projects from preclinical development through commercialization.

Coriolis operates a three-pillar service platform: Drug Product Development (including Accelerator Development Platforms and In Silico Modeling), Analytical Services under both R&D and GMP conditions, and Manufacturing Services for liquid and lyophilized drug products. Its proprietary COR-Competences® platform codifies 18 years of formulation science into standardized analytical workflows. The company integrates AI, machine learning, and digital twin technologies into its formulation development pipelines to predict drug candidate formulatability at late discovery stage and optimize formulations for clinical studies. Notable technical capabilities include SV-AUC methodology optimized for AAV gene therapy vectors (achieving up to 20-fold sample consumption reduction) and proprietary analytical approaches for particle identification and surfactant characterization.

The company generates revenue through project-based contracts for preclinical through commercial-stage services, with pricing managed via a consultative 'Request a Quote' model. Scale metrics include 845 global clients, 2,900+ completed projects, 980+ biotherapeutics supported, 165 formulations developed, 20 commercial products supported, and 160 peer-reviewed publications. In October 2023, KKR and Frontier Biosolutions executed a strategic growth investment to support global expansion and AI capability development, and in March 2026 Coriolis opened a US headquarters and laboratory in Durham, North Carolina.

Short descriptiontext

Coriolis Pharma is a Germany-based contract research and development organization specializing in biologics formulation, analytical services, and drug product manufacturing for pharmaceutical and biotech clients across multiple therapeutic modalities.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMartinsried, Germany
HQ citystring
Martinsried
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biologics formulation development, drug product development, analytical services, contract research organization, GMP manufacturing services
Industry4 codes
PRIMARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Biopharmaceutical Formulation & Drug Product Development Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research & Development Services
TypeProfessional Services
Description

Coriolis Pharma operates as a contract research and development organization (CRDO) providing formulation research, analytical services, and manufacturing services to pharmaceutical and biotech clients. Services are billed on a project/contract basis, likely through fixed-price or time-and-materials contracts. Revenue is generated from preclinical through commercial stage projects across multiple therapeutic modalities including antibodies, peptides, gene & cell therapy, viral vectors, nucleic acids, and vaccines.

coriolis-pharma.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1COR-Competences®
Description

Standardized analytical approaches built on 18 years of experience in drug product development, academic and applied research projects and continuous learning.

coriolis-pharma.com
Core offering1 text field

Coriolis Pharma is an independent contract research and development organization (CRDO) providing formulation research, analytical services, and GMP manufacturing services for biopharmaceutical drugs across multiple biological modalities (antibodies, peptides, therapeutic proteins, gene and cell therapies, viral vectors, nucleic acid therapeutics, vaccines, and nanoparticulate delivery systems). The company delivers project-based services spanning preclinical, early-phase, late-phase, and commercial stages, supported by its proprietary COR-Competences analytical platform and in silico / AI / digital twin formulation modeling capabilities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 980 different biotherapeutics supported across various modalities
+4 more records
Product overview1 text field

Coriolis Pharma is a contract research and development organization (CRDO) providing integrated drug product development, analytical services, and manufacturing services across multiple biological therapeutic modalities. The company operates a platform-based service model consisting of three core service pillars: Drug Product Development (including Accelerator Development Platforms and In Silico Modeling), Analytical Services (R&D and GMP), and Manufacturing Services (liquid and lyophilized drug products). Services span across therapeutic modalities including antibodies, peptides, therapeutic proteins, gene and cell therapies, viral vectors, nucleic acid therapeutics, vaccines, and nanoparticulate delivery systems. Development phases covered range from preclinical through commercial. The company also offers specialized computational capabilities using AI and machine learning for in silico formulation prediction and digital twin development.

Product and service14 records
1Drug Product Development Services
CategoryContract Research & Development Services
Description

Comprehensive formulation development services for biopharmaceutical drugs including preformulation studies, formulation development, lyophilization process development, comparability studies, stability studies, and biopharmaceutical process development, offered to pharmaceutical and biotech clients across development stages.

2Analytical Services (R&D and GMP)
CategoryContract Analytical Services
Description

Comprehensive analytical testing under R&D and GMP conditions including method development and validation, aggregate analytics, particle characterization, particle identification, surfactant characterization, higher-order structure analysis, functional assays, chemical change analysis, lyophilizate analytics, container closure integrity testing, basic formulation characterization, stability testing, and release testing for biologics.

3Manufacturing Services (Liquid and Lyophilized)
CategoryContract Manufacturing Services
Description

GMP process development and manufacturing services for liquid and lyophilized drug products, including manufacturing troubleshooting and support for biologics and ATMPs from preclinical through commercial stages.

4Accelerator Development Platforms
CategoryContract Research & Development Services
Description

Platform services for monoclonal antibody and antibody-like programs designed to accelerate preclinical and early-phase development, covering formulation screening, developability assessment, preformulation studies, and formulation development to enable rapid clinic entry.

5In Silico Formulation Modeling
CategoryComputational Formulation Services
Description

Computational modeling services using AI, machine learning, and digital twin technologies to predict drug candidate formulatability, assess biophysical properties, and select optimal lead formulations for clinical studies.

6Antibody and Antibody-Related Product Development
CategoryModality-Specific Development Services
Description

Formulation development and analytical services for monoclonal antibodies, antibody-drug conjugates, and antibody-related therapeutics, addressing high-concentration formulation, viscosity, and stability challenges.

7Gene and Cell Therapy Development
CategoryModality-Specific Development Services
Description

Formulation and analytical services for gene therapy and cell therapy products, including CAR-T cell starting material testing, viral vector characterization, AAV analysis, and lentiviral vector testing.

8Nucleic Acid Therapeutics Development
CategoryModality-Specific Development Services
Description

Formulation and drug product development for nucleic acid therapeutics including mRNA, siRNA, antisense oligonucleotides, and LNP-based delivery systems.

9Viral Vector Characterization Services
CategoryModality-Specific Development Services
Description

Specialized characterization and analytical services for viral vectors including AAV and lentiviral vectors used in gene therapy applications, featuring an optimized SV-AUC method for empty/full capsid differentiation.

10Vaccine Development Services
CategoryModality-Specific Development Services
Description

Formulation development and characterization services for vaccine products including prophylactic and therapeutic vaccines, addressing antigen stability and shelf-life extension.

11Preclinical Drug Development Services
CategoryPhase-Specific Development Services
Description

Early-stage formulation and analytical services to establish solid formulation foundations and reduce risks before clinical entry for biologic drug candidates.

12Early-Phase Drug Development Services
CategoryPhase-Specific Development Services
Description

Drug development support with robust analytical methods as drug products advance toward clinical trials.

13Late-Phase and Commercialization Services
CategoryPhase-Specific Development Services
Description

Phase III and BLA filing support including formulation refinement and regulatory preparation for commercialization.

14Commercial Services
CategoryPhase-Specific Development Services
Description

Post-approval services including release and stability testing, manufacturing troubleshooting, and lifecycle management reformulation for commercialized biologics.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-02
Description

Rentschler Biopharma, a global contract development and manufacturing organization (CDMO), and Coriolis Pharma announced a strategic collaboration to offer integrated biopharmaceutical solutions. The partnership combines Rentschler Biopharma's bioprocess development and manufacturing expertise with Coriolis Pharma's formulation and analytical capabilities, providing clients a unified interface from early development through commercial manufacturing. The integrated service offering is available starting December 2025, with both organizations operating in Germany and the United States. The partnership aims to reduce tech transfer risks and accelerate product timelines.

2Frontier Biosolutions
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-16
Description

Frontier Biosolutions is a specialized pharma services platform formed by KKR and Flerie to invest in companies specializing in advanced therapeutics. As the foundation of this platform, Frontier Biosolutions invested in Coriolis Pharma to expand its biologics and cell-gene therapy services. The partnership aims to leverage digital formulation approaches and AI technologies to enhance Coriolis's capabilities.

b3cnewswire.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

Coriolis Pharma co-hosts networking events with INCOG BioPharma Services during major industry conferences (TIDES, PEGS, ASGCT). The 'Science and Spirits – The Injectables Mixer' is an informal evening reception designed to foster new collaborations and strengthen professional relationships across the biologics and broader biopharma community.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Stevanato Group co-hosts networking events with Coriolis Pharma during major industry conferences (TIDES, PEGS, ASGCT). The collaboration at events like the 'Science and Spirits – The Injectables Mixer' brings together experts from biologics, gene and cell therapy, and the broader biopharma community.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

A German-headquartered CDMO specializing in biologics development and manufacturing. Directly comparable to Coriolis as both serve biopharma clients across biologics modalities, and the two companies have an active strategic collaboration announced in 2025.

TypeBroad incumbent
Description

One of the world's largest CDMOs with extensive biologics formulation, analytical, and manufacturing services. Comparable as a broad incumbent offering overlapping capabilities across the full biologics CMC spectrum that Coriolis addresses.

TypeBroad incumbent
Description

Large-scale global biologics CDMO providing process development, formulation, and GMP manufacturing. Comparable as a broad incumbent whose service portfolio overlaps materially with Coriolis's formulation and analytical offerings.

TypeBroad incumbent
Description

Major CDMO with biologics formulation, analytical, and drug product manufacturing capabilities across multiple modalities. Comparable to Coriolis as a broad incumbent serving biopharma with overlapping services.

TypeDirect peer
Description

A global CDMO focused on biologics and advanced therapies including cell/gene therapy. Comparable to Coriolis as a similarly-sized specialized CDMO offering formulation development, analytical services, and GMP manufacturing for biologics.

TypeBroad incumbent
Description

One of the largest biologics CDMOs globally, offering end-to-end discovery, development, and manufacturing services. Comparable to Coriolis as a broad incumbent competing across the biologics formulation and analytical value chain.

TypeBroad incumbent
Description

Global bioanalytical and contract laboratory services provider with extensive pharmaceutical testing offerings. Comparable to Coriolis in analytical, GMP release, and stability testing services supporting biopharma clients.

8Boehringer Ingelheim BioXcellence
TypeBroad incumbent
Description

Biopharmaceutical contract manufacturing arm of Boehringer Ingelheim, offering biologics process development, formulation, and commercial manufacturing. Comparable to Coriolis as a broad incumbent in biologics CMC services.

TypeEmerging player
Description

Provides analytical, formulation support, and GMP testing services to biopharma clients. Comparable to Coriolis as an analytical/formulation services provider, though with broader industry exposure beyond pure biologics.

TypeDirect peer
Description

Specialized injectable drug product CDMO focused on biologics fill-finish and formulation. Directly comparable as a similarly-sized CDMO serving biologics developers, and an active marketing co-host of Coriolis's networking events.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Coriolis Pharma

Biopharmaceutical Formulation & Drug Product Development Servicescoriolis-pharma.com

Coriolis Pharma is a Germany-based contract research and development organization specializing in biologics formulation, analytical services, and drug product manufacturing for pharmaceutical and biotech clients across multiple therapeutic modalities.

What Coriolis Pharma does

Coriolis Pharma is a privately-held contract research and development organization (CRDO) founded in 2008 in Martinsried, Germany, by Prof. Dr. Gerhard Winter of LMU Munich. The company specializes in formulation research, analytical services, and drug product manufacturing for biopharmaceutical drugs across multiple therapeutic modalities, including monoclonal antibodies, peptides, therapeutic proteins, gene and cell therapies, viral vectors, nucleic acid therapeutics, and vaccines. It serves pharmaceutical and biotech clients ranging from early-stage developers to large multinational pharmaceutical corporations, supporting projects from preclinical development through commercialization.

Coriolis operates a three-pillar service platform: Drug Product Development (including Accelerator Development Platforms and In Silico Modeling), Analytical Services under both R&D and GMP conditions, and Manufacturing Services for liquid and lyophilized drug products. Its proprietary COR-Competences® platform codifies 18 years of formulation science into standardized analytical workflows. The company integrates AI, machine learning, and digital twin technologies into its formulation development pipelines to predict drug candidate formulatability at late discovery stage and optimize formulations for clinical studies. Notable technical capabilities include SV-AUC methodology optimized for AAV gene therapy vectors (achieving up to 20-fold sample consumption reduction) and proprietary analytical approaches for particle identification and surfactant characterization.

The company generates revenue through project-based contracts for preclinical through commercial-stage services, with pricing managed via a consultative 'Request a Quote' model. Scale metrics include 845 global clients, 2,900+ completed projects, 980+ biotherapeutics supported, 165 formulations developed, 20 commercial products supported, and 160 peer-reviewed publications. In October 2023, KKR and Frontier Biosolutions executed a strategic growth investment to support global expansion and AI capability development, and in March 2026 Coriolis opened a US headquarters and laboratory in Durham, North Carolina.

Coriolis Pharma firmographics

Firmographics
Name
Coriolis Pharma
Legal name
Coriolis Pharma Research GmbH
Website
https://coriolis-pharma.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
101–250 employees
Short description
Coriolis Pharma is a Germany-based contract research and development organization specializing in biologics formulation, analytical services, and drug product manufacturing for pharmaceutical and biotech clients across multiple therapeutic modalities.
Ownership category
akta.pro rank

Coriolis Pharma industry classification

Industry
Product category
Biopharmaceutical Formulation & Drug Product Development Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Biologics formulation development
  • Drug product development
  • Analytical services
  • Contract research organization
  • GMP manufacturing services

Where Coriolis Pharma is headquartered

Location

Headquarters

HQ city
Martinsried
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

Coriolis Pharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Contract Research & Development Services: Coriolis Pharma operates as a contract research and development organization (CRDO) providing formulation research, analytical services, and manufacturing services to pharmaceutical and biotech clients. Services are billed on a project/contract basis, likely through fixed-price or time-and-materials contracts. Revenue is generated from preclinical through commercial stage projects across multiple therapeutic modalities including antibodies, peptides, gene & cell therapy, viral vectors, nucleic acids, and vaccines.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Coriolis Pharma product offering

Product offering

Core offering

Coriolis Pharma is an independent contract research and development organization (CRDO) providing formulation research, analytical services, and GMP manufacturing services for biopharmaceutical drugs across multiple biological modalities (antibodies, peptides, therapeutic proteins, gene and cell therapies, viral vectors, nucleic acid therapeutics, vaccines, and nanoparticulate delivery systems). The company delivers project-based services spanning preclinical, early-phase, late-phase, and commercial stages, supported by its proprietary COR-Competences analytical platform and in silico / AI / digital twin formulation modeling capabilities.

Product overview

Coriolis Pharma is a contract research and development organization (CRDO) providing integrated drug product development, analytical services, and manufacturing services across multiple biological therapeutic modalities. The company operates a platform-based service model consisting of three core service pillars: Drug Product Development (including Accelerator Development Platforms and In Silico Modeling), Analytical Services (R&D and GMP), and Manufacturing Services (liquid and lyophilized drug products). Services span across therapeutic modalities including antibodies, peptides, therapeutic proteins, gene and cell therapies, viral vectors, nucleic acid therapeutics, vaccines, and nanoparticulate delivery systems. Development phases covered range from preclinical through commercial. The company also offers specialized computational capabilities using AI and machine learning for in silico formulation prediction and digital twin development.

Differentiator

Problem solved

Functional benefit

Brands

  • COR-Competences®: Standardized analytical approaches built on 18 years of experience in drug product development, academic and applied research projects and continuous learning.

Products and services

  • Drug Product Development Services Comprehensive formulation development services for biopharmaceutical drugs including preformulation studies, formulation development, lyophilization process development, comparability studies, stability studies, and biopharmaceutical process development, offered to pharmaceutical and biotech clients across development stages.
  • Analytical Services (R&D and GMP) Comprehensive analytical testing under R&D and GMP conditions including method development and validation, aggregate analytics, particle characterization, particle identification, surfactant characterization, higher-order structure analysis, functional assays, chemical change analysis, lyophilizate analytics, container closure integrity testing, basic formulation characterization, stability testing, and release testing for biologics.
  • Manufacturing Services (Liquid and Lyophilized) GMP process development and manufacturing services for liquid and lyophilized drug products, including manufacturing troubleshooting and support for biologics and ATMPs from preclinical through commercial stages.
  • Accelerator Development Platforms Platform services for monoclonal antibody and antibody-like programs designed to accelerate preclinical and early-phase development, covering formulation screening, developability assessment, preformulation studies, and formulation development to enable rapid clinic entry.
  • In Silico Formulation Modeling Computational modeling services using AI, machine learning, and digital twin technologies to predict drug candidate formulatability, assess biophysical properties, and select optimal lead formulations for clinical studies.
  • Antibody and Antibody-Related Product Development Formulation development and analytical services for monoclonal antibodies, antibody-drug conjugates, and antibody-related therapeutics, addressing high-concentration formulation, viscosity, and stability challenges.
  • Gene and Cell Therapy Development Formulation and analytical services for gene therapy and cell therapy products, including CAR-T cell starting material testing, viral vector characterization, AAV analysis, and lentiviral vector testing.
  • Nucleic Acid Therapeutics Development Formulation and drug product development for nucleic acid therapeutics including mRNA, siRNA, antisense oligonucleotides, and LNP-based delivery systems.
  • Viral Vector Characterization Services Specialized characterization and analytical services for viral vectors including AAV and lentiviral vectors used in gene therapy applications, featuring an optimized SV-AUC method for empty/full capsid differentiation.
  • Vaccine Development Services Formulation development and characterization services for vaccine products including prophylactic and therapeutic vaccines, addressing antigen stability and shelf-life extension.
  • Preclinical Drug Development Services Early-stage formulation and analytical services to establish solid formulation foundations and reduce risks before clinical entry for biologic drug candidates.
  • Early-Phase Drug Development Services Drug development support with robust analytical methods as drug products advance toward clinical trials.
  • Late-Phase and Commercialization Services Phase III and BLA filing support including formulation refinement and regulatory preparation for commercialization.
  • Commercial Services Post-approval services including release and stability testing, manufacturing troubleshooting, and lifecycle management reformulation for commercialized biologics.

Quantifiable outcome

  • 980 different biotherapeutics supported across various modalities
  • +4 more outcomes

Companies that use Coriolis Pharma

Customer profile

Segments5 records

Ideal customer profiles4 records

Coriolis Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Coriolis Pharma partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Rentschler BiopharmacoreStrategic or Co-development Partner · 2 December 2025Rentschler Biopharma, a global contract development and manufacturing organization (CDMO), and Coriolis Pharma announced a strategic collaboration to offer integrated biopharmaceutical solutions. The partnership combines Rentschler Biopharma's bioprocess development and manufacturing expertise with Coriolis Pharma's formulation and analytical capabilities, providing clients a unified interface from early development through commercial manufacturing. The integrated service offering is available starting December 2025, with both organizations operating in Germany and the United States. The partnership aims to reduce tech transfer risks and accelerate product timelines.
  • Frontier BiosolutionscoreStrategic or Co-development Partner · 16 October 2023Frontier Biosolutions is a specialized pharma services platform formed by KKR and Flerie to invest in companies specializing in advanced therapeutics. As the foundation of this platform, Frontier Biosolutions invested in Coriolis Pharma to expand its biologics and cell-gene therapy services. The partnership aims to leverage digital formulation approaches and AI technologies to enhance Coriolis's capabilities.
  • INCOG BioPharma ServicesminorGTM or Marketing PartnerCoriolis Pharma co-hosts networking events with INCOG BioPharma Services during major industry conferences (TIDES, PEGS, ASGCT). The 'Science and Spirits – The Injectables Mixer' is an informal evening reception designed to foster new collaborations and strengthen professional relationships across the biologics and broader biopharma community.
  • Stevanato GroupminorGTM or Marketing PartnerStevanato Group co-hosts networking events with Coriolis Pharma during major industry conferences (TIDES, PEGS, ASGCT). The collaboration at events like the 'Science and Spirits – The Injectables Mixer' brings together experts from biologics, gene and cell therapy, and the broader biopharma community.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Coriolis Pharma competitors and assessment

Company assessment

Direct peers

  • Rentschler Biopharma: A German-headquartered CDMO specializing in biologics development and manufacturing. Directly comparable to Coriolis as both serve biopharma clients across biologics modalities, and the two companies have an active strategic collaboration announced in 2025.
  • AGC Biologics: A global CDMO focused on biologics and advanced therapies including cell/gene therapy. Comparable to Coriolis as a similarly-sized specialized CDMO offering formulation development, analytical services, and GMP manufacturing for biologics.
  • INCOG BioPharma Services: Specialized injectable drug product CDMO focused on biologics fill-finish and formulation. Directly comparable as a similarly-sized CDMO serving biologics developers, and an active marketing co-host of Coriolis's networking events.

Broad incumbents

  • Lonza: One of the world's largest CDMOs with extensive biologics formulation, analytical, and manufacturing services. Comparable as a broad incumbent offering overlapping capabilities across the full biologics CMC spectrum that Coriolis addresses.
  • Samsung Biologics: Large-scale global biologics CDMO providing process development, formulation, and GMP manufacturing. Comparable as a broad incumbent whose service portfolio overlaps materially with Coriolis's formulation and analytical offerings.
  • Catalent: Major CDMO with biologics formulation, analytical, and drug product manufacturing capabilities across multiple modalities. Comparable to Coriolis as a broad incumbent serving biopharma with overlapping services.
  • WuXi Biologics: One of the largest biologics CDMOs globally, offering end-to-end discovery, development, and manufacturing services. Comparable to Coriolis as a broad incumbent competing across the biologics formulation and analytical value chain.
  • Eurofins Scientific: Global bioanalytical and contract laboratory services provider with extensive pharmaceutical testing offerings. Comparable to Coriolis in analytical, GMP release, and stability testing services supporting biopharma clients.
  • Boehringer Ingelheim BioXcellence: Biopharmaceutical contract manufacturing arm of Boehringer Ingelheim, offering biologics process development, formulation, and commercial manufacturing. Comparable to Coriolis as a broad incumbent in biologics CMC services.

Emerging players

  • Intertek Pharmaceutical Services: Provides analytical, formulation support, and GMP testing services to biopharma clients. Comparable to Coriolis as an analytical/formulation services provider, though with broader industry exposure beyond pure biologics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Coriolis Pharma social profiles

Digital presence

Coriolis Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Coriolis Pharma leadership team

Management profile

Number of profiles

Profiles5 records

Coriolis Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Coriolis Pharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Coriolis Pharma M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Coriolis Pharma

What does Coriolis Pharma do?

Coriolis Pharma is an independent contract research and development organization (CRDO) providing formulation research, analytical services, and GMP manufacturing services for biopharmaceutical drugs across multiple biological modalities (antibodies, peptides, therapeutic proteins, gene and cell therapies, viral vectors, nucleic acid therapeutics, vaccines, and nanoparticulate delivery systems). The company delivers project-based services spanning preclinical, early-phase, late-phase, and commercial stages, supported by its proprietary COR-Competences analytical platform and in silico / AI / digital twin formulation modeling capabilities.

Is Coriolis Pharma a public or private company?

Coriolis Pharma is a private company. It is classified as private equity controlled and is currently operating.

When was Coriolis Pharma founded?

Coriolis Pharma was founded in 2008. It employs 101 to 250 people.

Where is Coriolis Pharma based?

Coriolis Pharma is headquartered in Martinsried, Germany, in the Europe region.

How does Coriolis Pharma make money?

One revenue line is on record: contract Research & Development Services.

Who are Coriolis Pharma's main competitors?

Direct peers on record are Rentschler Biopharma, AGC Biologics and INCOG BioPharma Services. Broad incumbents are Lonza, Samsung Biologics, Catalent, WuXi Biologics, Eurofins Scientific and Boehringer Ingelheim BioXcellence. Intertek Pharmaceutical Services is listed as an emerging player.

Does Coriolis Pharma have an API?

No public API is recorded for Coriolis Pharma.

What industry is Coriolis Pharma in?

Coriolis Pharma's product category is Biopharmaceutical Formulation & Drug Product Development Services. Its primary akta.pro industry code is HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development), with a secondary code of HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ContractpharmaCoriolis Pharma Opens New Site in North CarolinaCoriolis Pharma has opened a new U.S. headquarters and laboratory in North Carolina's Research Triangle Park. The new site provides advanced services in formulation and drug product development, with full capabilities expected by late 2026.Coriolis-PharmaDigital and In Silico Transformation in Biologics FormulationCoriolis Pharma is integrating AI, machine learning, and digital twin technologies into biologics formulation development to assess drug candidate formulatability at the late discovery stage, enabling developers to reduce technical risk and accelerate timelines before clinical testing begins. While billions have flowed into AI-driven drug discovery and clinical development, formulation science remains relatively underinvested despite its critical role in determining whether promising candidates become viable drug products. The article outlines Coriolis's multiscale modeling approach, the scientific, financial, and cultural challenges of digital transformation, and the company's goal of ultimately developing predictive digital twins for drug formulation.News-MedicalRentschler Biopharma and Coriolis Pharma announce strategic collaboration for integrated biopharma solutionsRentschler Biopharma, a global contract development and manufacturing organization (CDMO), and Coriolis Pharma, a contract research and development organization (CRDO) specializing in formulation research, announced a strategic collaboration to offer integrated biopharma solutions. The partnership combines Rentschler Biopharma's bioprocess development and manufacturing expertise with Coriolis Pharma's formulation and analytical capabilities, providing clients a unified interface from early development through commercial manufacturing. The integrated service offering will be available starting December 2025, with both organizations operating in Germany and the United States.GlobeNewswireRentschler Biopharma and Coriolis Pharma announce strategic collaboration for integrated biopharma solutionsRentschler Biopharma and Coriolis Pharma announced a strategic collaboration to provide seamless, end-to-end biopharmaceutical solutions from early formulation through commercial manufacturing. The partnership combines Rentschler's bioprocess development and manufacturing expertise with Coriolis's formulation research and analytical capabilities, offering clients reduced complexity, faster timelines, and lower tech transfer risks. The integrated service offering will be available starting December 2025, with both companies maintaining operations in Germany and the United States.GenengnewsRentschler Biopharma and Coriolis Pharma Collaborate on Integrated Biopharma SolutionsCDMO Rentschler Biopharma and CRDO Coriolis Pharma have entered into a collaboration to offer clients end-to-end biopharma solutions, combining Rentschler's bioprocess development and manufacturing expertise with Coriolis's formulation and drug product development capabilities. The integrated service offering will be available to clients starting this month. Both organizations have operations in Germany and the U.S., enabling them to serve clients across these key biopharma markets.NewsobserverMorrisville’s $1 billion biotech hub announces its first tenant, a German companyGerman pharmaceutical services company Coriolis Pharma has announced a $10 million investment to establish its first U.S. laboratory at the Spark Life Science hub in Morrisville, North Carolina, creating 50 jobs. The decision was driven by Morrisville's proximity to RDU International Airport, top-tier universities, and manufacturing partners, distinguishing it from other biotech hubs like Boston. This marks the first tenant for the $1 billion campus after it sat empty for seven months, serving as a proof of concept amid mixed signals in the broader biotech market.Coriolis-PharmaLeveraging Advanced GMP Release and Stability Testing Methods to Accelerate New Drug DevelopmentCoriolis Pharma outlines its approach to leveraging Good Manufacturing Practice (GMP)-compliant analytical methods to accelerate drug development and ensure product stability. The company provides a tiered framework of testing services, ranging from non-GMP R&D methods to fully validated GMP assays, tailored for complex modalities like biologics and cell therapies. This strategy aims to integrate analytics early in the development lifecycle to mitigate risks and maintain regulatory compliance through commercialization.Business InsiderCoriolis Pharma Launches New U.S. Entity and Platform ServicesCoriolis Pharma launched a new U.S. entity and two platform services to accelerate antibody drug development. The services include a developability assessment platform and a systemic antibody pre-formulation platform, offering multiple pricing models. The company aims to support U.S. clients with local presence and international expertise.